BioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 15, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) grant. This non-dilutive funding will support a new research initiative at BioHar
Biotechnologies, Pharmaceutique, Santé
2026-07-15 7:30 AM EDT | BioHarvest Sciences Inc.
Years of Preparation. One Regulatory Approval. Commercial Launch Begins: CBIH Receives Texas License for Consumable Hemp Products
Houston, Texas--(Newsfile Corp. - July 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that the State of Texas has approved the Company's license to manufacture and distribute consumable hemp products. This approval turns years of vision, science, and preparation into action and marks the moment CBIH steps into the market and begins commercial distribution. The Company e
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-07-15 7:00 AM EDT | Cannabis Bioscience International Holdings
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today significant progress in the protection of its proprietary innovations across key international markets. The company has received multiple favorable patent actions encompassing three
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-15 7:00 AM EDT | Phio Pharmaceuticals Corp.
Telescope Announces Changes to its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of intelligent automation and advanced chemical manufacturing technologies, announces that Ali Pejman has resigned from the Company's Board of Directors ("Board"), effective as of the date of this press release. Henry Dubina, CEO, stated, "On behalf of the Board and management, I would li
Technologies, Produits chimiques, Pharmaceutique
2026-07-14 7:32 PM EDT | Telescope Innovations Corp.
Nextleaf Evolves Glacial Gold, Building Trust with Wellness Consumers
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to announce the evolution of Glacial Gold, the Company's flagship consumer cannabis brand. The most significant evolution in Glacial Gold's history, a milestone that reflects Nextleaf's continued development into a consumer-packaged goods ("CPG") comp
Biotechnologies, Pharmaceutique, Cannabis, Extracteurs de cannabis
2026-07-13 9:29 AM EDT | Nextleaf Solutions Ltd.
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today announced the prioritization of its lead clinical-stage asset, BETR-001, to pursue migraine and other primary headache disorders as its lead indications. The strategic focus concentrates BETR-001's development on one of the largest, most disabling and most underserved areas of neurology, and does so through a serotonin-receptor me
2026-07-13 8:00 AM EDT | BetterLife Pharma Inc.
BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on July 22, 2026.
Biotechnologies, Pharmaceutique, Santé
2026-07-13 8:00 AM EDT | BioHarvest Sciences Inc.
BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of John W. LaRocca, Esq. to its Board of Directors. Mr. LaRocca will also serve as a member of the Company's Audit Committee. Mr. LaRocca is a three-decade biopharmaceutical in
2026-07-09 8:00 AM EDT | BetterLife Pharma Inc.
TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering over 1 Million Lives
Highlights Meuhedet Health Services, Israel's third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed's flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now accepted by two of Israel's four national HMOs—Maccabi Healthcare Services and Meuhedet—providing institutional access to approximately four million insured
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-07-09 7:00 AM EDT | TempraMed Technologies Ltd.
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine company is pleased to announce that it has filed its application under the Bahamas Longevity and Regenerative Therapies Act (LARTA) for a commercial Phase I Basket Clinical Trial evaluating VesCell™ in patients suffering from vascular dementia, refractory angina and pain.
Biotechnologies, Pharmaceutique, Santé
2026-07-08 10:08 AM EDT | Hemostemix Inc.
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, today announced the opening of a new office at McMaster Innovation Park in Hamilton, Ontario, supporting the Company's expanding radiopharmaceutical research and business development a
Biotechnologies, Pharmaceutique, Santé
2026-07-08 3:15 AM EDT | Defence Therapeutics Inc.
Extendicare Announces Timing of 2026 Second Quarter Results and Conference Call
Markham, Ontario--(Newsfile Corp. - July 7, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced today that it plans to release its financial results for the second quarter of 2026 after market close on Thursday, August 6, 2026. A conference call hosted by Michael Guerriere, President and Chief Executive Officer and David Bacon, Executive Vice President and Chief Financial Officer, will be held on Friday, August 7, 2026, at 11:30 a.m. (EDT) to discuss the result
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-07 8:00 AM EDT | Extendicare Inc.
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered into an amendment (the "Amendment") to the previously announced definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp., a who
Biotechnologies, Pharmaceutique
2026-07-06 6:20 PM EDT | Mentari Therapeutics, Inc.
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Nucro-Technics Inc. ("Nucro") to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is a potent neuroplastogen an
2026-07-06 8:00 AM EDT | BetterLife Pharma Inc.
CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings
Houston, Texas--(Newsfile Corp. - July 6, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announces that Dante Picazo, Chief Executive Officer of the Company, has designated 500,000,000 shares of common stock from his personal holdings to honor the directors, employees, and key associates whose dedication, loyalty, and work have helped shape CBIH's journey and strengthen the Company through years
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-07-06 7:00 AM EDT | Cannabis Bioscience International Holdings
TempraMed Signs LOI for Exclusive Distribution in Kuwait, Expanding Presence in High-Growth Gulf Region Healthcare Market
Highlights TempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir Trading Kuwait represents a high-value market with significant demand for insulin, GLP-1 therapies, biologics, and other temperature-sensitive medications LOI includes minimum annual purchase commitments in Year 1 Expands TempraMed's footprint across the Middle East and supports broa
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-07-06 7:00 AM EDT | TempraMed Technologies Ltd.
Custom Health Delivers US$51.6 Million Proforma Annualized Revenue Run-Rate in Q1-2026
For the three months ended March 31, 2026, Custom Health achieved quarterly revenue of US$4.3 million, while InnovativeRx (as defined below) achieved record quarterly revenue of US$8.6 million, reflecting total consolidated quarterly revenue of US$12.9 million and proforma annualized revenue run-rate(1) of US$51.6 million. Custom Health successfully completed its public listing and started trading on the Toronto Stock Exchange on June 24,
Technologies, Pharmaceutique, Santé
2026-07-03 6:00 AM EDT | Custom Health Holdings Inc.
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium. Presentation Details Date: Thursday, July 9, 2026 Time: 2:30 p.m. Eastern Daylight Time Live Presentation: Available on Kiora's Investor Relations homepage at ir.ki
Biotechnologies, Pharmaceutique
2026-07-02 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Herbal Dispatch Announces Vesting of RSUs and Satisfaction of Certain Outstanding Fees
Vancouver, British Columbia--(Newsfile Corp. - July 2, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company") is providing this update in furtherance to its news release dated January 2, 2026, whereby it announced the granting in aggregate of 2,760,000 restricted share units ("RSUs"). The RSUs which were granted to certain officers, directors, employees, and consultants of the Company pursuant to the Company's
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-07-02 3:01 AM EDT | Herbal Dispatch Inc.
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has filed and obtained a receipt for a final base shelf prospectus dated June 29, 2026 ("P
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-06-30 4:30 PM EDT | Theralase Technologies Inc.